Novonesis started 2026 with a 7% organic sales growth and a robust adjusted EBITDA margin of 37.8% in Q1, driven by growth across all sales areas and markets. The company confirmed its 2026 outlook with expected organic sales growth of 5-7% and an EBITDA margin between 37-38%. Key highlights include strong performance in Food & Health and Planetary Health Biosolutions, successful bond issuance, and acquisition of a production facility in Thailand to support expansion. Despite global uncertainties, Novonesis remains confident in achieving its long-term growth targets through continued demand for biosolutions.
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign featuring a series of vibrant summer events including the 50th Sun Life Hong Kong International Dragon Boat Festival, Pixar Summer Fest, and a major football event with top Euro...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign, featuring festivals, family attractions, sports events, and exclusive summer deals valid until August 31. Highlights include the 50th Sun Life Hong Kong International Dragon Bo...
